Omeros Corporation (NASDAQ:OMER) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Omeros Corporation (NASDAQ:OMER) have been assigned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $30.33.

A number of research analysts recently weighed in on OMER shares. Cantor Fitzgerald reissued an “overweight” rating and set a $22.00 target price on shares of Omeros in a report on Wednesday, October 14th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Finally, Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th.

Insider Activity at Omeros

In related news, Director Arnold Hanish sold 10,000 shares of Omeros stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the sale, the director owned 5,000 shares of the company’s stock, valued at approximately $94,750. The trade was a 66.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Peter Cancelmo sold 25,000 shares of Omeros stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the sale, the vice president directly owned 200 shares of the company’s stock, valued at $3,708. The trade was a 99.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 105,906 shares of company stock worth $1,989,705. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Omeros

Several hedge funds have recently bought and sold shares of OMER. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Omeros by 3.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,708 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 589 shares in the last quarter. Sterling Capital Management LLC boosted its position in shares of Omeros by 75.3% in the third quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 758 shares during the period. International Assets Investment Management LLC boosted its position in shares of Omeros by 16.0% in the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 800 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of Omeros by 13.6% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,500 shares of the biopharmaceutical company’s stock valued at $333,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Brighton Jones LLC grew its stake in shares of Omeros by 9.9% in the third quarter. Brighton Jones LLC now owns 34,739 shares of the biopharmaceutical company’s stock valued at $661,000 after acquiring an additional 3,142 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Stock Performance

Omeros stock opened at $18.18 on Thursday. Omeros has a 52 week low of $6.24 and a 52 week high of $21.24. The stock has a market capitalization of $1.32 billion, a P/E ratio of 14.20 and a beta of 2.96. The stock has a 50-day simple moving average of $18.45 and a 200 day simple moving average of $13.55.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Research analysts forecast that Omeros will post -0.37 earnings per share for the current year.

Omeros Company Profile

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.